SEB Asset Management AB Makes New Investment in IDEXX Laboratories, Inc. $IDXX

SEB Asset Management AB bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 36,527 shares of the company’s stock, valued at approximately $20,524,000.

Other institutional investors have also made changes to their positions in the company. SHP Wealth Management bought a new position in IDEXX Laboratories in the 4th quarter worth $26,000. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $26,000. Park Place Capital Corp bought a new position in shares of IDEXX Laboratories in the fourth quarter worth about $29,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares during the period. Finally, Wormser Freres Gestion boosted its stake in IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $567.44 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a 50 day simple moving average of $554.49 and a 200 day simple moving average of $599.33. IDEXX Laboratories, Inc. has a fifty-two week low of $513.02 and a fifty-two week high of $769.98. The firm has a market cap of $44.76 billion, a P/E ratio of 41.78, a P/E/G ratio of 3.10 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the business earned $2.91 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research analyst reports. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Stifel Nicolaus cut their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. UBS Group reduced their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.